

P. Myles has received an unrestricted educational grant from F. Hoffman La Roche for research in the area of pandemic influenza (this grant is being used to fund a systematic review and IPD analysis investigating the public health impact of antivirals in pandemic influenza).

J.S. Nguyen-Van-Tam has received funding to attend influenza related meetings, lecture and consultancy fees and research funding from several influenza antiviral drug and vaccine manufacturers. All forms of personal remuneration ceased in September 2010, but influenza-related research funding from GlaxoSmithKline, F. Hoffmann-La Roche and Astra-Zeneca is current. He is a former employee of SmithKline Beecham plc. (now GlaxoSmithKline), Roche Products Ltd, and Aventis-Pasteur MSD (now Sanofi-Pasteur MSD), all prior to 2005, with no outstanding pecuniary interests by way of shareholdings, share options or accrued pension rights.

M.G. Semple is a clinical advisor to the Health Protection Agency and Department of Health, England.

S.J. Brett has received consultancy fees from GlaxoSmithKline and Baxter.

B. Bannister is an employee of the Department of Health, England.

J.E. Enstone has received consultancy fees from GlaxoSmithKline and performed paid work for the Department of Health, England.

K.G. Nicholson has received H5 avian influenza vaccines from Novartis and H1N1 pandemic influenza vaccines from GlaxoSmithKline and Baxter to facilitate MRC and NIHR-funded trials. He has received consultancy fees from Novartis and GlaxoSmithKline and lecture fees from Baxter. A colleague of K.G. Nicholson at the University Hospitals of Leicester NHS Trust was Principal Investigator and recipient of research funding from Roche on antiviral resistance and from Novartis on pandemic H1N1 vaccines.

P.J. Openshaw is paid as a scientific advisor to GSK, Mucosis and Kenta Biotech on RSV vaccination, unrelated to the present work. He is vice-president (unpaid) of the European Scientific Working group on Influenza (ESWI), an organisation that promotes the application of research to reduce the burden of influenza in Europe. ESWI meetings are supported by unrestricted grants from vaccine manufacturers.

W.S. Lim has received an unrestricted educational grant from Pfizer for an unrelated pneumonia study.